Skip to main content
Explore URMC

menu

Gastrointestinal (pancreas) Cancer: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Research Question:
Will the study drug (Glufosfamide) work as well as Fluorouracil (5-FU), the approved treatment, in treating pancreatic cancer?

Basic Study Information

Purpose:
Glufosfamide is being compared against Fluorouracil (5-FU). Fluorouracil is approved by the FDA for use in people with rectal cancer. 5-FU was the drug of choice for pancreatic cancer before gemcitabine and is still used in multiple regimens such as folfox and Folfirinox as part of standard of care. The study drug is made of glucose (a sugar made by the body) and a substance which damages or kills cancer cells. Cancer cells depend on sugar more than normal cells do, so the cancer cells may take up more of the study drug than normal cells. This may allow glufosfamide to attack the cancer cells without causing excessive damage to the normal cells.

Location: Cancer Center
Study Web URL:  http://clinicaltrials.gov/ct2/show/NCT01954992?term=Glufosfamide+Compared+with+Fluorouracil&rank=1
Study Reference #: IGIP-14032

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Kari_Steinmetz
Phone: (585) 276-4447
Email: Kari_Steinmetz@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Pancreatic Cancer

Return to Search